2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5556 Women versus men with essential thrombocythemia: A comparative analysis of phenotype, genotype, and outcomes in 2,922 patients

Naseema Gangat, MBBS, Amina Akram, MBBS2, Giuseppe Gaetano Loscocco, MD, PhD3, Merry Nakhleh4, Aysel Bayraktar5, Abiola Bolarinwa6, Buraq Ahmed7, Fahad Hassan Gunjial8, Giulio Capecchi9, Valentina Boldrini10, Kebede Begna, M.D.11, Michelle Elliott, MD12, Kaaren Reichard, MD13, Rong He, MD14, Cinthya J Zepeda Mendoza15, Animesh Pardanani, PhD, MBBS16, Alessandro Vannucchi, MD17, Ayalew Tefferi, MD18, Paola Guglielmelli, MD, PhD19
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Rochester, United States
3 University of Florence, Florence, Italy
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Rochester, United States
9 University of Florence, Florence, Italy
10 University of Florence, Florence, Italy
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Rochester, United States
17 University of Florence, Florence, Italy
18 Mayo Clinic, Rochester, United States
19 University of Florence, Florence, Italy

Background: Essential thrombocythemia (ET) is prognostically the most favorable, among myeloproliferative neoplasms (MPNs; median survival exceeding 3 decades in young patients). ET exhibits female preponderance (2:1) and women with ET live longer than their male counterparts (AJH. 2025;100:2017). The current study examines differences between women and men with ET in regard to clinical presentation, genotype, disease course, and survival outcomes.

Methods:

Patients with ET were retrospectively recruited from the Mayo Clinic and University of Florence MPN databases, which served as the derivation and validation cohorts, respectively. Disease complications were defined according to conventional criteria (Blood 2016;127:2391). Overall survival (OS) was estimated by Kaplan-Meier method whereas thrombosis and disease transformation rates were analyzed using competing-risk methods. Multivariable and sex-stratified analyses were adjusted for established risk factors.  

Results:

Mayo Clinic cohort (N=1500)

Phenotype and Genotype: 992 (66%) patients were women and 508 (34%) men. Compared to men, women were younger (median age 59 vs. 60 years; p=0.04) and had a lower prevalence of diabetes (9% vs. 15%; p<0.01), hypertension (45% vs. 53%; p<0.01), smoking history (20% vs. 32%; p<0.01), extreme thrombocytosis ≥1,000 × 10?/L; 21% vs. 27%; p<0.01), and arterial thrombosis (11% vs. 19%; p<0.01). JAK2 (67% vs. 53%, p<0.01) and triple-negative (10% vs. 7%, p=0.02) mutations were higher in women and CALR (20% vs. 36%) in men (all p<0.01). Among 271 NGS-evaluable patients, IDH2, PHF6, and ZRSR2 mutations were detected only in men (4% vs. 0% each; all p=0.03). Cytogenetic abnormalities were less frequent in women (6% vs. 10%, p=0.03).

Thrombosis and disease transformation rates: Women had a lower incidence of arterial thrombosis than men (10-year: 12.7% vs. 18.5%; 20-year: 17.8% vs. 25.0%; revised IPSET-thrombosis adjusted p<0.01). In contrast, venous thrombosis rates were similar (10-year: 8.8% vs. 10.3%; 20-year: 17.4% vs. 17.2%; p=0.56). Women displayed a lower incidence of myelofibrotic progression (10-year: 8.4% vs. 12.1%; risk-adjusted p<0.01) whereas leukemic transformation rates were similar between the two sexes (10-year: 1.4% vs. 2.5%; risk-adjusted p=0.55).

Overall survival and risk factors: After a median follow-up of 7.7 years, mortality risk was lower in women (23% vs. 30% deaths); a 30% lower risk in risk-adjusted analysis (HR 0.70; p<0.01). Older age, absolute neutrophil count (ANC ≥8 × 109/L), and prior arterial thrombosis were adverse prognostic factors in both sexes. Additional risk factors in women included AMC ≥0.5 x 109/L (HR 1.9), ALC <1.7 x 109/L (HR 1.5), JAK2 mutation (HR 2.0), and platelet count ≥1,000 × 10?/L (HR 1.7). Additional risk factor in men included prior venous thrombosis (HR 1.5) while AMC ≥0.5 x 109/L and ALC <1.7 x 109/L were not significant in men. The Triple A+ model classified women into ultra-low  (n=316, 32%), low  (n=446, 45%), and high-risk (n=230, 23%) categories, with median OS: 37.2, 21.1, 16 years, respectively; notably, none of the women were classified in the intermediate-risk category.Addition of JAK2 mutation and platelet count ≥1,000 × 10?/L to the Triple A+ model further stratified the high risk group with median OS of 9.3 vs. 16 years (HR 2.8; p<0.01).

 

University of Florence cohort (N=1,422)

Among 1,422 patients, women (n=916, 64%) demonstrated findings similar to the Mayo cohort, including younger age (median; 58 vs 61 years), fewer cardiovascular risk factors, less extreme thrombocytosis (17% vs. 20%), more frequent JAK2 and triple-negative disease, and less frequent CALR mutations (12% vs. 26%) (all p<0.05). Among 331 NGS-evaluable patients, ASXL1, EZH2, and U2AF1 mutations were less frequent in women (all p<0.04). Women had lower rates of arterial thrombosis (9% vs. 14%) , myelofibrotic and leukemic transformation and superior OS (all p<0.01), whereas venous thrombosis rates were comparable. The Triple A+ model stratified OS into ultra-low- (median; not reached), low- (38 years), high-risk (16 years) (p<0.01). Addition of JAK2 mutation and extreme thrombocytosis further stratified the high-risk group (median OS 12 vs. 16 years;p=0.20).

Conclusions: The current study underlines reproducible sex-specific differences in phenotype, genotype, disease course, and survival in ET. The demonstration of gender-specified risk factors warrants sex-specific revision of formal risk models.

Naseema Gangat, MBBS: No relevant conflicts of interest to declare.